Story perspectives

Johnson & Johnson Halts Atopic Dermatitis Drug Trial

12/26/2025

34 2

Summary

Story summary

Johnson & Johnson disclosed on October 10, 2025 that it discontinued a mid-stage study of JNJ-5939 for moderate to severe atopic dermatitis after an interim analysis failed to meet efficacy goals, with the drug being well-tolerated.
Atopic dermatitis affects over 100 million people globally.
The company is pursuing other experimental programs, including NM26, PX128, PX130, and KP-723.
Existing approved treatments include Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq.

1 of 1

Story summary

Johnson & Johnson disclosed on October 10, 2025 that it discontinued a mid-stage study of JNJ-5939 for moderate to severe atopic dermatitis after an interim analysis failed to meet efficacy goals, with the drug being well-tolerated.
Atopic dermatitis affects over 100 million people globally.
The company is pursuing other experimental programs, including NM26, PX128, PX130, and KP-723.
Existing approved treatments include Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq.